Elevated serum beta 2-microglobulin levels and C1q-binding immune complexes in sarcoidosis

Area of Science:

• Immunology
• Clinical Medicine
• Biochemistry

Background:

• Sarcoidosis is a multisystem inflammatory disease of unknown etiology.
• Biomarkers for sarcoidosis activity are crucial for monitoring disease progression and treatment efficacy.
• Elevated serum beta 2 microglobulin (β2M) has been observed in various inflammatory conditions.

Purpose of the Study:

• To investigate serum beta 2 microglobulin (β2M) levels in sarcoidosis patients.
• To explore the relationship between β2M, immune complexes, and C-reactive protein (CRP) in sarcoidosis.
• To assess the potential of β2M as a biomarker for sarcoidosis activity.

Main Methods:

• Serum samples from 32 sarcoidosis patients without renal dysfunction and healthy controls were analyzed.
• Measurements included serum beta 2 microglobulin (β2M), C1q-binding immune complexes, and C-reactive protein (CRP).
• β2M levels were monitored during disease relapses and under corticosteroid therapy.

Main Results:

• Serum β2M levels were significantly higher in sarcoidosis patients (3.05 ± 0.98 mg/l) compared to controls (1.54 ± 0.22 mg/l).
• Low levels of C1q-binding immune complexes were found in 70% of patients, and CRP in 55%, irrespective of extra-thoracic manifestations.
• Neither immune complexes nor CRP correlated with β2M levels; however, β2M increased during relapses and decreased with effective corticosteroid treatment.

Conclusions:

• Serum beta 2 microglobulin (β2M) is elevated in sarcoidosis patients without renal impairment.
• β2M levels correlate with disease activity, rising during relapses and responding to corticosteroid treatment.
• β2M shows promise as a valuable biological marker for monitoring sarcoidosis activity.